We scan new podcasts and send you the top 5 insights daily.
After scaling his first startup to 70 people and feeling the pain of being overstaffed, the founder overcorrected with his second company. Despite raising a $10M seed round, he hired no one for a long time, realizing later that this caution had slowed down progress, especially on the engineering side.
Figma's CEO reflects that despite clear signals of user demand, like a 14-page feature request after a buggy demo, he was too nervous to hire aggressively. This slowed their progress unnecessarily in the early years, a mistake he advises other founders to avoid.
Scaling to $2M ARR with only two co-founders led to severe burnout and created a business entirely dependent on them. This made it difficult to step away or sell, highlighting the risk of staying too lean for too long.
Despite healthy revenue, the bootstrapped founder questioned if $30k MRR was the ceiling and hired engineers one by one, with long pauses in between. This risk-averse approach created a significant bottleneck, causing the entire company to move slower than necessary during a critical growth phase.
Flexport's CEO advises founders who've raised a large round to immediately implement a 90-day hiring freeze. This prevents the team from defaulting to hiring as the solution to every problem, reinforcing a culture of internal problem-solving and preventing the new capital from creating bloat and slowing the company.
Resist hiring quickly after finding traction. Instead, 'hire painfully slowly' and assemble an initial 'MVP Crew' — a small, self-sufficient team with all skills needed to build, market, and sell the product end-to-end. This establishes a core DNA of speed and execution before scaling.
Paul Graham argues that a large team is a greater liability than low cash when a startup needs to pivot. Having many employees forces the founders to find a new idea that fits the existing team's capabilities, drastically limiting their options compared to a small founding team that can pursue anything.
A common failure mode for well-funded biotechs is growing headcount too rapidly. Immunocore's CEO advises new leaders to pace themselves, emphasizing that drug development is a marathon. Prematurely scaling creates fixed expenses that can drain capital before key scientific milestones are hit.
The 'Founder Mode' concept, meant to encourage founders to reclaim decision-making, is often misinterpreted as a reason to avoid hiring senior executives. Ben Horowitz warns this is dangerous, as scaling functions like a global sales team requires deep experience that can't be learned on the founder's nickel.
Despite having raised $1M, the Juicebox founders remained a two-person team. The reason wasn't just to stay lean; it was a belief that their early, "risky, unproven" company couldn't yet attract the A-player talent they aspired to hire. This self-awareness protected them from making suboptimal early hires.
If an entrepreneur's first attempt at delegation goes poorly, it can instill the false lesson that no one else can be trusted. This prevents future hiring and stunts the company's growth, trapping the founder in an unsustainable, hands-on role.